Immunogenicity Testing

Immunogenicity is the ability of a particular substance induce a humoral and/or cell-mediated immune responses. An immune response can be potentially elicited by administering any substance into the human body.

Products which increase the potential of anti-drug antibodies include :

Therapeutic antibodies, enzyme therapies, peptides and combination products.

An immune response may also impact a drug’s safety and efficacy. Assays should be designed in such a way that they provide sufficient sensitivity and are free from potential risks to the target patient population. By designing assays with these factors, it is possible to gather data about the strength and type of immune response that a drug may produce in humans.

  • Bridging ELISA
  • Type II hypersensitivity reaction
  • Clinical Trial Support
  • Total Antibody Assay
  • Enzyme Linked Immuno Sorbent Assay (ELISA)

Related Conference of Immunogenicity Testing

June 28-30 2020

Stroke Summit 2020

June 15-16, 2020

24th Global Congress on Biotechnology

London, UK
July 15-16, 2020

12th World Congress and Expo on Stem Cell Research

Prague, Czech Republic
July 15-16, 2020

25th World Biotechnology Congress

London, UK
September 21-22, 2020

14th International Conference on Genomics & Pharmacogenomics

Vancouver, Canada
September 23-24, 2020

24th European Biotechnology Congress

Berlin, Germany
October 19-20, 2020

7th Asia Pacific Geriatrics and Gerontology Congress

Tokyo, Japan
October 23-24, 2020

2nd International Conference on Biomarkers and Cancer Targets

Cape Town, South Africa
November 16-17, 2020

International Conference on Genomics and Molecular Biology

Lisbon, Portugal
November 23-24, 2020

International Conference on Toxicogenomics

Bali, Indonesia
December 07-08, 2020

2nd World Congress on Cell and Structural Biology

Sydney, Australia

Immunogenicity Testing Conference Speakers

Recommended Sessions

Related Journals

Are you interested in